Australia markets open in 2 hours 49 minutes

GeNeuro SA (GNRRF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.55000.0000 (0.00%)
As of 09:33AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close4.5500
Open4.5500
Bid0.0000 x 0
Ask0.0000 x 0
Day's range4.5500 - 4.5500
52-week range3.1400 - 4.5500
Volume125
Avg. volume247
Market cap57.888M
Beta (5Y monthly)0.46
PE ratio (TTM)N/A
EPS (TTM)-0.4730
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Presentation at American Neurological Association Congress Confirms Potential of GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic Lateral Sclerosis

    GENEVA, Switzerland, October 18, 2021--Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that the NINDS, part of the U.S. National Institutes of Health (NIH), presented novel pre-clinical results at the American Neurological Association (ANA) annual meeting, October 17-19, confirming in pre-clinical models of ALS the neurotoxic properties of HERV-K ENV, a ret

  • Business Wire

    GeNeuro Reports 2021 Half-Year Results and Provides Corporate Update

    GENEVA, September 29, 2021--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO) (Paris:GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported its half-year financial results for the period ending June 30, 2021 and provided a corporate update.

  • Business Wire

    GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID

    GENEVA, September 24, 2021--GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis, announces today that it has entered into a research agreement with Northwestern University to further investigate the relationship between HERV-W ENV (W-ENV) and long-COVID neuropsychiatric syndromes.